Zai Lab/$ZLAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zai Lab
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Ticker
$ZLAB
Sector
Primary listing
Employees
1,784
Headquarters
Website
Zai Lab Metrics
BasicAdvanced
$2.1bn
-
-$1.62
0.84
-
Price and volume
Market cap
$2.1bn
Beta
0.84
52-week high
$39.32
52-week low
$15.96
Average daily volume
738k
Financial strength
Current ratio
2.404
Quick ratio
1.841
Long term debt to equity
1.829
Total debt to equity
35.033
Interest coverage (TTM)
-42.85%
Profitability
EBITDA (TTM)
-227.012
Gross margin (TTM)
8.11%
Net profit margin (TTM)
-39.29%
Operating margin (TTM)
-53.50%
Effective tax rate (TTM)
0.83%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-13.36%
Return on equity (TTM)
-24.19%
Valuation
Price to revenue (TTM)
4.466
Price to book
3.08
Price to tangible book (TTM)
3.5
Price to free cash flow (TTM)
-15.238
Free cash flow yield (TTM)
-6.56%
Free cash flow per share (TTM)
-1.206
Growth
Revenue change (TTM)
8.36%
Earnings per share change (TTM)
-34.83%
3-year revenue growth (CAGR)
25.17%
3-year earnings per share growth (CAGR)
-27.68%
What the Analysts think about Zai Lab
Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.
Zai Lab Financial Performance
Revenues and expenses
Zai Lab Earnings Performance
Company profitability
Zai Lab News
AllArticlesVideos
U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
Business Wire·3 days ago
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
Business Wire·2 weeks ago
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.